Brexit & the future landscape for clinical trial supplies in the UK and Europe
Pharma Industry, Regulatory, Supply Chain
The UK’s long-standing regulatory alignment with the EU ended with Brexit. The relationship officially ended on 01st January 2021. Collectively, industries across the spectrum held their breath with none of the actors sure what was going to happen next. There was widespread concern that significant disruption would ensue. However, despite some early bumps in the road, the initial transition was relatively smooth.
As time moves on, some of the longer term impacts will begin to be felt. In this summary paper, the GCSG Regulatory e-Team examines the immediate changes that have impacted the clinical supply chain from QP certification to import and VAT considerations. We also look at what the future may hold and end on the question as to the UK’s future in the clinical supply chain as the EU readies itself for the clinical trial regulation.
We would love for you to share your feedback and experiences in the post-Brexit world! Please leave your questions and comments on the GCSG Regulatory forum.
Download the position paper
Related Education Resources.
All ResourcesThe Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
2020 Virtual Conference: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members
EAP 102: Part 2 of Introduction to EAP
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning, Project Management, Strategic Planning
Presentation
Members
